Background: Adjuvant chemoradiation (CRT) is standard for head and neck squamous cell carcinoma (HNSCC) patients with positive margins or extranodal extension (ENE) following surgery. However, emerging evidence suggests the number of positive lymph nodes (LNs) is the dominant determinant of survival in non-oropharyngeal HNSCC and thus may better identify those benefiting from treatment intensification. Results: In total, 7144 patients met inclusion criteria. In multivariable analysis, increasing number of positive LNs was associated with both increasing mortality (P < 0.001) and increasing benefit from postoperative CRT versus RT alone (interaction P < 0.001). While there was no benefit from postoperative CRT in patients with 0-2 LNþ [hazard ratio (HR) 0.96, 95% confidence interval (CI) 0.86-1.07, P ¼ 0.47], increased benefit was seen in those with 3-5 LNþ (HR 0.84, 95% CI 0.70-1.00, P ¼ 0.05) and those with 6 LNþ (HR 0.65, 95% CI 0.51-0.82, P < 0.001) in multivariable models. By contrast, margin status and ENE did not reliably identify patients benefitting from postoperative CRT based on statistical tests of interaction. Even in patients with ENE, positive margins, or both, only those with 6 LNþ had improved survival with postoperative CRT.
Introduction
Postoperative chemoradiation (CRT) is considered a standard of care for head and neck squamous cell carcinoma (HNSCC) patients with positive margins or extranodal extension (ENE) following surgery [1] . This is based on a post hoc combined analysis of two randomized trials (RTOG 95-01, EORTC 22931) that showed improved locoregional control and overall survival (OS) with postoperative CRT versus radiotherapy (RT) alone only in this subgroup of patients [2] [3] [4] [5] . However, CRT also significantly increases toxicity, so further refining which patients are most likely to benefit from multimodality adjuvant therapy is important for optimizing the risks and benefits of treatment.
Recent studies have demonstrated that the number of metastatic cervical lymph nodes (LNs) is the most important factor influencing survival in non-oropharyngeal HNSCC, far exceeding the impact of classic high-risk factors like ENE and positive margins [6, 7] . Thus, it is possible that nodal burden also represents the best indicator of which patients will benefit from intensified adjuvant therapy in non-oropharyngeal HNSCC. In this study, we evaluate the interaction between quantitative metastatic LN burden and postoperative CRT with respect to survival in oral cavity, laryngeal, and hypopharyngeal squamous cell carcinoma. We then compare the utility of metastatic LN burden, versus other pathologic factors, for determining which patients benefit from postoperative CRT using a large national dataset.
Methods Database information
Deidentified patient data were obtained through the National Cancer Database (NCDB), a hospital-based registry maintained by the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The NCDB collects cases from >1500 facilities encompassing approximately 70% of newly diagnosed cancers in the United States. Given that this study used deidentified data from a publicly available data source, the current study was deemed to be exempt from full Institutional Review Board review by Cedars-Sinai Medical Center.
Patient selection
The NCDB was queried for patients with non-metastatic HNSCC of the oral cavity, larynx, and hypopharynx diagnosed between 2004 and 2014 (supplementary Figure S1 , available at Annals of Oncology online). Included patients underwent curative-intent surgical resection and postoperative radiation to doses between 5400 and 6600 cGy. To ensure adequate assessment of involved LNs, patients were required to have at least 10 LNs dissected. Those receiving RT or chemotherapy before surgery, with unknown timing of chemotherapy with respect to RT, with unknown pathologic staging information, with unknown number of positive LNs, or with unknown ENE or margin status, were excluded. CRT was defined as receipt of systemic therapy within 7 days of radiation initiation. High-volume facilities were defined as top 1% of institutions by volume.
Statistical analysis
See supplementary material, available at Annals of Oncology online, for full statistical methods. The mechanism of missing covariable data was examined using the method proposed by Little [8] and multiple imputation was carried out [9] .
Cox regression was used for univariate and multivariable analyses. Multivariable analyses were carried out using backwards stepwise selection. The proportional hazards assumptions were assessed with Schoenfeld residuals and interactions with time. Multicollinearity was assessed using the variable inflation factor (VIF). Propensity scores were estimated for each patient, and propensity score-matched cohorts were created using the nearest neighbor method with a caliper of 0.2 [10] .
The number of positive LN was modeled as a restricted cubic spline function to allow for their nonlinear association with OS. The relationship between CRT versus RT and the number of positive LN was modeled as a nonlinear interaction term. The model was truncated at 10 positive LN due to instability in estimates of the influence of CRT versus RT on OS beyond this, due to small numbers of patients with higher numbers of positive LNs. Change points were estimated using a piecewise linear regression model [11] . Multivariable subgroup analysis with tests of interaction was carried out to evaluate the effect of CRT versus RT alone on survival across various subgroups [12] . All statistical analyses were carried out using R statistical software (version 3.4.4; R Foundation, Vienna, Austria).
Results

Patient characteristics
In total, 7144 patients met inclusion criteria, including 2465 undergoing postoperative CRT and 4679 undergoing postoperative RT (supplementary Figure S1 , available at Annals of Oncology online). Median follow-up was 47 months. CRT cases had a higher incidence of LN positivity (76.8% versus 38.0%, P < 0.001), higher average number of positive LN (3.1 versus 1.0, P < 0.001), higher rates of ENE (47.7% versus 11.6%, P < 0.001), and more patients with positive margins (21.7% versus 11.7%, P < 0.001) than RT cases (Table 1) . Though the CRT cohort had a higher proportion of younger patients (median age 59 versus 62 years, P < 0.001), the Charlson-Deyo comorbidity indices were similar (P ¼ 0.39).
Predictors of survival
In multivariable analysis, increasing number of metastatic LNs was associated with increased mortality [6 positive LNs: hazard ratio (HR) 3.444, 95% confidence interval (CI) 2.879-4.119, P < 0.001], as were ENE (HR 1.203, 95% CI 1.081-1.338, P < 0.001) and positive margins (HR 1.287, 95% CI 1.171-1.415, P < 0.001), albeit less strongly ( Table 2, supplementary Table S1 , available at Annals of Oncology online). Postoperative CRT was associated with improved survival compared with postoperative RT alone (HR 0.871, 95% CI 0.797-0.951, P ¼ 0.002). Similar results were observed when modeling number of positive LNs as a nonlinear-continuous variable using restricted cubic splines (supplementary Table S2 , available at Annals of Oncology online).
Influence of positive LN number on OS benefit from postoperative CRT In a multivariable model with all first-order interactions between CRT and other covariates, the only pathologic covariate imparting a significant interaction on postoperative CRT's effect on OS was the number of positive LN (interaction P < 0.001). To model this effect, we allowed for a nonlinear relationship between the interaction of CRT and positive LN number with respect to survival and then determined the ratio of the predicted relative hazards for postoperative CRT versus RT as a function of the continuous positive LN number. In this model, an increasing OS advantage from postoperative CRT versus RT was observed as the number of positive LN increased, with change points in this interaction identified at two LN and five LN (Figure 1 ).
Using these established change points, the effect of postoperative CRT versus RT on OS was assessed in subgroups of patients with 0-2, 3-5, and 6 positive LNs. A test of interaction between these subgroups and the OS benefit of postoperative CRT versus RT showed a strong interaction after adjusting for other covariables (interaction P < 0.001), with increasing benefit of CRT as positive LN number increased ( Figure 2 ). In multivariable Cox regression (supplementary Table S3 , available at Annals of Oncology online), patients with 6 metastatic LNs had a robust Interactions between ENE, margin status, and other pathologic factors on CRT benefit
When assessing other pathologic variables, including ENE, margin status, LN size, and T-stage, none significantly predicted differential benefit from postoperative CRT versus RT alone based on tests of interaction (Figure 2) . Notably, as in previous analyses of postoperative CRT [4] , improved OS was observed for patients with either ENE and/or positive margins (HR ¼ 0.820, 95% CI 0.724-0.929, P ¼ 0.002), but not in patients without either of these high-risk factors (HR ¼ 0.911, 95% CI 0.805-1.032, P ¼ 0.14). Similar results were seen in propensity score-matched cohorts (supplementary Figure S2 , available at Annals of Oncology online). Despite this, a test of interaction between postoperative CRT and combined ENE/margin status was not significant (interaction P ¼ 0.17). Similarly, there was no significant interaction between postoperative CRT and either ENE (interaction P ¼ 0.70) or margin status (P ¼ 0.83) when considering these high-risk features individually.
Sensitivity analyses
Because postoperative CRT is currently the accepted standard of care for patients with ENE and/or positive margins, we assessed the influence of number of positive LN in this subgroup (N ¼ 2464). We found an increasing survival benefit from postoperative CRT with increasing number of positive LNs in this subgroup (interaction P ¼ 0.029) (Figure 4) . The HRs for the effect of postoperative CRT in each LN group were nearly identical to what was observed in the unselected overall cohort. No benefit from postoperative CRT was observed in patients with positive margins and ENE and low metastatic LN burden.
Discussion
In patients with non-oropharyngeal HNSCC undergoing surgical resection and postoperative radiation, we observed an increasing survival benefit from concomitant CRT as the number of positive LNs increased. Improved survival with postoperative CRT was noted beginning at three positive LN, with most of the benefit seen in the 'very-high-risk' group of patients with 6 positive LNs. This cohort, representing 8% of patients in this study, had a 35% decrease in the relative risk of death with CRT versus RT following surgery after adjusting for other covariables, corresponding to a nearly 23% absolute improvement in 3-year OS in propensity score-matched cohorts. No benefit from CRT was seen for patients with low metastatic nodal burden. An identical pattern, with CRT only benefitting patients with high quantitative nodal burden, was observed even when limiting analysis to the subgroup of patients with positive margins and/or ENE, a cohort of patients who are uniformly recommended to undergo postoperative CRT in national guidelines. Our results support quantitative nodal burden as the single most powerful predictor identifying patients that will have improved survival outcomes with intensification of adjuvant therapy. Surprisingly, we found that unlike the 'very-high-risk' patients identified by metastatic LN number, standard high-risk factors like ENE or margin status were not able to accurately discriminate between patients benefiting or not benefiting from postoperative CRT. Although these results at first may appear to conflict with the combined analysis of EORTC 22931 and RTOG 9501 [4] , our data are actually remarkably consistent with what was reported in that study; it is primarily our statistical methodology and interpretation that differ. As in the combined analysis, we found that patients with either ENE or positive margins had improved OS with postoperative CRT versus RT alone (HR ¼ 0.70 in combined analysis versus HR ¼ 0.82 in our study). Also, as in the combined analysis, there was no statistically significant benefit for postoperative CRT versus RT alone in those without ENE or positive margins in our study. Thus, our results corroborate the main combined EORTC/ RTOG analysis findings and give validity that our results are not driven predominantly by selection bias. However, unlike the combined analysis, we carried out formal statistical tests of interaction when evaluating these covariates and found no statistically significant interaction between the effect of postoperative CRT and ENE, margin status, or both factors combined. In other words, the differential survival benefit from postoperative chemoradiation in patients with positive margins and/or ENE versus those without these features was present but relatively small, with substantial overlap of the 95% CIs, in comparison to the vast difference in CRT benefit observed when stratifying by number of positive LNs. Interestingly, when looking at specifically at margin status alone, there was not even a trend toward increased benefit from chemoradiation in patients with positive margins, in contrast to what was observed with ENE. In the combined EORTC/RTOG analysis, margin status and ENE were not analyzed as individual factors, so it is unclear if this finding is consistent with what was observed in these trials.
There are several other important differences between our study and the combined analysis of RTOG 9501 and EORTC 22931 [4] . The combined analysis did not specifically assess the effect of number of positive LNs. It is probable that many patients with positive margins or ENE also had high metastatic nodal burden, making it difficult to separate the independent effects of these correlated variables. Our cohort size is also larger than the combined analysis, allowing greater power to detect statistical interactions. There may have been relatively few patients in RTOG 9501 and EORTC 22931 with 6 LNs, limiting the ability to analyze this very-high-risk cohort in these trials. Lastly, our analysis specifically excluded oropharyngeal cancers (30% and 42% of the EORTC and RTOG cohorts, respectively), which are biologically and clinically distinct from other head and neck cancers [13, 14] and may have a different relationship with nodal burden, [15] [16] [17] , ENE [18, 19] , and margin status [20] .
Although our results challenge conventional wisdom in HNSCC, we believe that they are built on a credible foundation. We have previously demonstrated that the number of metastatic cervical LNs is by far the strongest predictor of survival in nonoropharyngeal HNSCC, substantially surpassing the impact of other factors like ENE and positive margins [6, 7] . Our current data support these prior findings. Patients with 6 LNs were approximately 250% more likely to die than node-negative patients (adjusted HR ¼ 3.44), in comparison to a 20% increase in mortality for patients with ENE and a 29% increase in mortality for those with positive margins, respectively, when adjusting for other covariates. It is intuitive that the patients with the most to gain from intensification of adjuvant therapy are those who are most likely to die of their disease. Thus, the benefit of postoperative concomitant CRT in patients with high metastatic nodal burden may primarily reflect the biologic aggressiveness for HNSCC with extensive regional metastasis, requiring intense multimodality therapy in order to optimize outcomes. However, we would also note that other powerful predictors of survival, such as tumor stage, had limited ability to identify patients benefiting from CRT, suggesting that the biology and patterns of recurrence of lymphotropic HNSCC may result in postoperative CRT being uniquely beneficial for this population. This warrants additional investigation.
Although patients with high nodal burden benefitted the most from concomitant CRT, outcomes for those with 6 positive LNs remain poor in comparison to other patients even with multimodality therapy, suggesting that further adjuvant treatment intensification beyond postoperative CRT in this 'very-high-risk' subset may be needed to optimize outcomes. Patients with a high metastatic LN burden therefore represent an ideal population for testing novel adjuvant therapeutic strategies, such as the combination of postoperative CRT with immune checkpoint inhibitors, as in NRG HN003, or targeted molecular therapies [21] . It is also possible that some of the oncologic benefits of postoperative CRT are abrogated in lower risk patients as a result of toxicity, either due to direct mortality, inability to receive standard doses or types of chemotherapy, or prolongation of RT. Therefore, innovations in supportive care that widen the therapeutic window for postoperative CRT may allow a broader group of patients to benefit from multimodality therapy. Future clinical trials are needed to move beyond the current standard of care for adjuvant therapy in HNSCC in these patients.
Numerous limitations deserve mention. First, our results are not applicable to oropharyngeal cancers, which are biologically distinct and excluded from this analysis. Also, characteristics of patients receiving postoperative CRT and RT were different in this retrospective study, with CRT patients generally having more aggressive tumor features and being somewhat younger. We rigorously statistically balanced the CRT and RT groups with respect to a variety of tumor and demographic characteristics using multivariable regression and propensity score matching, but it is possible that unmeasured confounding variables could influence our results. Specifically, the NCDB lacks information on perineural invasion, performance status, body mass index, marital status, and smoking status, all of which can influence survival in HNSCC. Nevertheless, it is reassuring that our results generally recapitulated what was observed in the combined analysis of RTOG 9501 and EORTC 22931. Additionally, data on the type and duration of systemic therapy were lacking. Cisplatin is currently the only systemic agent that has demonstrated a survival benefit in the postoperative setting, so the influence of patients receiving other regimens is unclear. It also is not possible to adjust for radiation quality, which has been shown to be a critical determinant of survival in prior studies [22] . However, we did require all patients to receive standard doses of postoperative RT, and we adjusted for facility volume in all analyses. Lastly, NCDB only has data on OS, but does not report other relevant end points such as locoregional control, distant metastasis, and cause-specific mortality. It is likely that concomitant CRT may improve certain clinically relevant outcomes, like locoregional control, in a broader group of patients who observed to have an OS benefit in our study, potentially justifying concomitant CRT in other circumstances.
In conclusion, we found that the number of metastatic cervical LNs was the strongest factor predicting a survival benefit from postoperative CRT in non-oropharyngeal HNSCC. Patients with higher numbers of positive LNs derived more relative and absolute improvements in OS from postoperative CRT than patients with lower LN burden, with largest impact observed in the 'very-highrisk' subset of patients with 6 positive LNs. Margin positivity, ENE, or both factors combined did not reliably discriminate patients benefiting from postoperative CRT compared with postoperative RT. In combination with previous data showing that the number of positive LNs is the most powerful driver of survival after surgery for nonoropharyngeal HNSCC, these results challenge conventional dogma regarding adjuvant therapy intensification. Our data strongly 
